Zacks Company Profile for Cidara Therapeutics, Inc. (CDTX : NSDQ) |
|
|
|
Company Description |
Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California.
Number of Employees: 38 |
|
|
|
Price / Volume Information |
Yesterday's Closing Price: $50.45 |
Daily Weekly Monthly
 |
20 Day Moving Average: 1,331,251 shares |
Shares Outstanding: 20.16 (millions) |
Market Capitalization: $1,017.26 (millions) |
Beta: 1.14 |
52 Week High: $56.83 |
52 Week Low: $10.14 |
Short Interest Ratio: |
|
% Price Change |
% Price Change Relative to S&P 500 |
4 Week |
92.78% |
87.00% |
12 Week |
152.25% |
118.66% |
Year To Date |
87.69% |
77.32% |
|
|
|
|
|
|
|
General Corporate Information |
Officers
Jeffrey Stein - President and Chief Executive Officer
Daniel D. Burgess - Chairman
Frank Karbe - Chief Financial Officer
Bonnie Bassler - Directors
Carin Canale-Theakston - Directors
|
|
Peer Information
Cidara Therapeutics, Inc. (CORR.)
Cidara Therapeutics, Inc. (RSPI)
Cidara Therapeutics, Inc. (CGXP)
Cidara Therapeutics, Inc. (BGEN)
Cidara Therapeutics, Inc. (GTBP)
Cidara Therapeutics, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 171757206
SIC: 2836
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/12/25
|
|
Share - Related Items
Shares Outstanding: 20.16
Most Recent Split Date: 4.00 (0.05:1)
Beta: 1.14
Market Capitalization: $1,017.26 (millions)
|
|
|
|
|
|
EPS Information |
Dividend Information |
Analyst Coverage: No |
Dividend Yield: 0.00% |
Current Fiscal Quarter EPS Consensus Estimate: $-1.33 |
Indicated Annual Dividend: $0.00 |
Current Fiscal Year EPS Consensus Estimate: $-7.02 |
Payout Ratio: |
Number of Estimates in the Fiscal Year Consensus: 2.00 |
Change In Payout Ratio: |
Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
Next EPS Report Date: 08/12/25 |
|
|
|
|